Bio Plus Co

Bio Plus Co Net Tangible Assets

The Net Tangible Assets of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 171.80 B KRW. In the previous year, Net Tangible Assets was 125.71 B KRW — a change of 36.66% (higher).

Net Tangible Assets

171.80 BKRW

YoY

36.66%

Last updated:

Net Tangible Assets of Bio Plus Co is 2025 171.80 B KRW. Net Tangible Assets of Bio Plus Co was 2024 125.71 B KRW. It decreases by 36.66% higher compared to the previous year.

The Bio Plus Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
5.53 B KRW
Jan 1, 2019
15.82 B KRW
Jan 1, 2020
26.57 B KRW
Jan 1, 2021
76.05 B KRW
Jan 1, 2022
110.65 B KRW
Jan 1, 2023
121.03 B KRW
Jan 1, 2024
125.71 B KRW
Jan 1, 2025
171.80 B KRW
The Bio Plus Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
171.80 BKRW+36.66%
125.71 BKRW+3.86%
121.03 BKRW+9.38%
110.65 BKRW+45.50%
76.05 BKRW+186.23%
26.57 BKRW+67.91%
15.82 BKRW+186.11%
5.53 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Net Tangible Assets of Bio Plus Co is 171.80 B KRW in 2025.

Net Tangible Assets of Bio Plus Co changed from 125.71 B KRW to 171.80 B KRW, representing a 36.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bio Plus Co

All Key Metrics — Bio Plus Co